165 related articles for article (PubMed ID: 35653749)
1. In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity.
Gao Y; Zhao J; Huang Z; Zhao H; Guo Z; Ma S; Tang X; Song W; Chen X
ACS Biomater Sci Eng; 2023 Jul; 9(7):4108-4116. PubMed ID: 35653749
[TBL] [Abstract][Full Text] [Related]
2. OX40, OX40L and Autoimmunity: a Comprehensive Review.
Webb GJ; Hirschfield GM; Lane PJ
Clin Rev Allergy Immunol; 2016 Jun; 50(3):312-32. PubMed ID: 26215166
[TBL] [Abstract][Full Text] [Related]
3. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
4. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.
Jacquemin C; Augusto JF; Scherlinger M; Gensous N; Forcade E; Douchet I; Levionnois E; Richez C; Lazaro E; Duffau P; Truchetet ME; Seneschal J; Couzi L; Pellegrin JL; Viallard JF; Schaeverbeke T; Pascual V; Contin-Bordes C; Blanco P
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568041
[TBL] [Abstract][Full Text] [Related]
5. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
6. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
7. OX40 and OX40L Interaction in Cancer.
Lu X
Curr Med Chem; 2021; 28(28):5659-5673. PubMed ID: 33372866
[TBL] [Abstract][Full Text] [Related]
8. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
9. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
Redmond WL; Weinberg AD
Crit Rev Immunol; 2007; 27(5):415-36. PubMed ID: 18197805
[TBL] [Abstract][Full Text] [Related]
10. Induction of Antigen-Independent Proliferation of Regulatory T-Cells by TNF Superfamily Ligands OX40L and GITRL.
Kumar P; Arbieva ZH; Maienschein-Cline M; Ganesh BB; Ramasamy S; Prabhakar BS
Methods Mol Biol; 2021; 2248():63-71. PubMed ID: 33185867
[TBL] [Abstract][Full Text] [Related]
11. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
12. The significance of OX40 and OX40L to T-cell biology and immune disease.
Croft M; So T; Duan W; Soroosh P
Immunol Rev; 2009 May; 229(1):173-91. PubMed ID: 19426222
[TBL] [Abstract][Full Text] [Related]
13. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
van Wanrooij EJ; van Puijvelde GH; de Vos P; Yagita H; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):204-10. PubMed ID: 17068285
[TBL] [Abstract][Full Text] [Related]
14. OX40 (CD134) and OX40L.
Gough MJ; Weinberg AD
Adv Exp Med Biol; 2009; 647():94-107. PubMed ID: 19760068
[TBL] [Abstract][Full Text] [Related]
15. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Deng J; Zhao S; Zhang X; Jia K; Wang H; Zhou C; He Y
Onco Targets Ther; 2019; 12():7347-7353. PubMed ID: 31564917
[TBL] [Abstract][Full Text] [Related]
16. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
17. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
[TBL] [Abstract][Full Text] [Related]
18. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation.
Wang HC; Klein JR
J Immunol; 2001 Dec; 167(12):6717-23. PubMed ID: 11739485
[TBL] [Abstract][Full Text] [Related]
19. The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.
Nuebling T; Schumacher CE; Hofmann M; Hagelstein I; Schmiedel BJ; Maurer S; Federmann B; Rothfelder K; Roerden M; Dörfel D; Schneider P; Jung G; Salih HR
Cancer Immunol Res; 2018 Feb; 6(2):209-221. PubMed ID: 29321210
[TBL] [Abstract][Full Text] [Related]
20. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
Front Immunol; 2019; 10():879. PubMed ID: 31105701
[No Abstract] [Full Text] [Related]
[Next] [New Search]
